Prevalence of depression among patients with multiple sclerosis in Erbil city

  • Warzheen Yaseen Sulaiman Department of Psychiatry, College of Medicine, Hawler Medical University, Erbil, Iraq.
  • Sirwan Kamil Ali Department of Psychiatry, College of Medicine, Hawler Medical University, Erbil, Iraq.
Keywords: Depression, Patients with multiple sclerosis, Erbil city

Abstract

Background and objective: Multiple sclerosis is one of the chronic central nervous system diseases. Depression comorbidity is common with multiple sclerosis. This study aimed to determine the prevalence of depression among patients with multiple sclerosis and the relation of patient demographic data and disease status.

Methods: A cross-sectional study was conducted in Rizgary Teaching Hospital in Erbil City, in a one-year duration from October 2017 to October 2018. The sample size was 169 known patients with multiple sclerosis, which was collected randomly. Beck Depression Inventory was used. The statistical package for the social sciences (version 25) was used for data analysis. Pearson Chi-square and Fisher's Exact Test were used to finding the association between various variables and depression.

Results: The prevalence of depression among patients with multiple sclerosis was 53.5%. Age group more than 50 years was found more depressed (66.7 %,P = 0.006). Depression is more with those with multiple sclerosis for 10 years and more (84.6%) with a statistically significant association (P = 0.021). Treatment by rituximab show more depression (85.7%,P = 0.039). The frequency of severity of major depressive disorder was (mild 31.8%, moderate 52.9%, and severe 15.3%) and showed no significant association with different variables.

Conclusion: The prevalence of depression among patients with multiple sclerosis was high. The age group of more than 50 years, duration of multiple sclerosis equal or more than 10 years, and rituximab treatment were regarded as risk factors.

References

Kingwell E, Marriott JJ, Jetté N, Pringsheim T, Makhani N, Morrow SA, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 2013; 13:128.

Newland P, Starkweather A, Sorenson M. Central fatigue in multiple sclerosis: a review of the literature. J Spinal Cord Med 2016; 39(4):386– 99.

Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008; 71(2):129–35.

Vargas GA, Arnett PA. Attributional style and depression in multiple sclerosis: the learned helplessness model. Int J MS Care 2013; 15(2):81–9.

Goldenberg MM. Multiple sclerosis review. P T 2012; 37(3):175–84.

Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol 2011; 9(3):409–16.

Schippling S, O'Connor P, Knappertz V, Pohl C, Bogumil T, Suarez G, et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol 2016; 263(7):1418–26.

Marrie RA, Fisk JD, Tremlett H, Wolfson C, Warren S, Tennakoon A, et al. Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology 2015; 85(22):1972–9.

Marrie RA, Reingold S, Cohen J,Stuve O, Trojano M, Sorensen PS, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler 2015; 21(3):305–17.

Skokou M, Soubasi E, Gourzis P. Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations. ISRN Neurol 2012; 2012:427102.

Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 2005; 76(4):469–75.

Beal CC, Stuifbergen AK, Brown A. Depression in multiple sclerosis: a longitudinal analysis. Arch Psychiatr Nurs 2007; 21(4):181–91.

Brigitta B. Pathophysiology of depression and mechanisms of treatment. Dialogues Clin Neurosci 2002; 4(1):7–20.

Joffe RT. Depression and multiple sclerosis: a potential way to understand the biology of major depressive illness. J Psychiatry Neurosci 2005; 30(1):9–10.

Pucak ML, Carroll KA, Kerr DA, Kaplin AI. Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression. Dialogues Clin Neurosci 2007; 9(2):125–39.

Johansson S, Gottberg K, Kierkegaard M, Ytterberg C. Variations in and predictors of the occurrence of depressive symptoms and mood symptoms in multiple sclerosis: a longitudinal two-year study. BMC Neurol 2016; 16:32.

Pinto EF, Andrade C. Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem. Curr Neuropharmacol 2016; 14(7):743–8.

Raosoft. Sample Size Calculator 2016. (Accessed November 7, 2016, available at: http://www.raosoft.com/samplesize.html).

Skokou M, Soubasi E, Gourzis P. Depression in Multiple Sclerosis: A Review of Assessment and Treatment Approaches in Adult and Pediatric Populations. ISRN Neurol 2012; 2012:427102.

Lee EH, Lee SJ, Hwang ST, Hong SH, Kim JH. Reliability and Validity of the Beck Depression Inventory-II among Korean Adolescents. Psychiatry Investig 2016; 14(1):30–6.

Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry 2002; 159(11):1862–8.

Greenberg B, Fan Y, Carriere L, Sullivan A. Depression and Age at First Neurology Appointment Associated with Receipt of Behavioral Medicine Services Within 1 Year in a Multiple Sclerosis Population. Int J MS Care 2017; 19(4):199–207.

Moore S. Major depression and multiple sclerosis - a case report. J Med Life 2013; 6(3):290–1.

Voinov B, Richie WD, Bailey RK. Depression and chronic diseases: it is time for a synergistic mental health and primary care approach. Prim Care Companion CNS Disord 2013; 15(2):PCC.12r01468.

Bhattacharjee S, Goldstone L, Ip Q, Warholak T. Depression Treatment among Adults with Multiple Sclerosis and Depression in Ambulatory Care Settings in the United States. Mult SclerInt 2017; 2017:3175358.

Al-Asmi A, Al-Rawahi S, Al-Moqbali ZS, Al-Farsi Y, Essa MM, El-Bouri M, et al. Magnitude and concurrence of anxiety and depression among attendees with multiple sclerosis at a tertiary care Hospital in Oman. BMC Neurol 2015; 15:131.

Gorial FI, Swady RN. Prevalence of Depression in Iraqi Patients with Systemic Sclerosis and Its Relationship with Disease Severity. International Journal of Medical Research & Health Sciences 2018; 7(4):69–74.

Patten SB, Beck CA, Williams JV, Barbui C, Metz LM. Major depression in multiple sclerosis: a population-based perspective. Neurology 2003; 61(11):1524–7.

Braley TJ, Chervin RD. Fatigue in Multiple Sclerosis: Mechanisms, Evaluation, and Treatment. Sleep 2010; 33(8):1061–7.

Jones SM, Amtmann D. The relationship of age, function, and psychological distress in multiple sclerosis. Psychol Health Med 2014; 20(6):629–34.

Gold R, Wolinsky JS, Amato MP, Comi G. Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord 2010; 3(6):351–67.

Chwastiak LA, Ehde DM. Psychiatric issues in multiple sclerosis. Psychiatr Clin North Am 2007; x

(4):803–17.

Rahn K, Slusher B, Kaplin A. Cognitive impairment in multiple sclerosis: a forgotten disability remembered. Cerebrum 2012; 2012:14.

Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clin Cases 2015; 3(7):545–55.

Randall KL. Rituximab in autoimmune diseases. AustPrescr 2016; 39(4):131–4.

Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol 2011; 9(3):409–16.

Kwiatkowska B, Kłak A, Maślińska M, Mańczak M, Raciborski F. Factors of depression among patients with rheumatoid arthritis. Reumatologia 2018; 56(4):219–27.

Fluge Ø, Mella O. Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series. BMC Neurol 2009; 9:28.

Xie Q, Li X, Sun J, Yuan B, Li Y, Wang L, et al. A meta-analysis to determine the efficacy and tolerability of anti-B-cell monoclonal antibodies in multiple sclerosis. Exp Ther Med 2017; 13(6):3061–6.

Lana-Peixoto MA, Teixeira AL, Haase VG. Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis. Arq Neuropsiquiatr 2002; 60(3-B):721–4.

Published
2020-08-30
How to Cite
Sulaiman, W., & Ali, S. (2020). Prevalence of depression among patients with multiple sclerosis in Erbil city. Zanco Journal of Medical Sciences (Zanco J Med Sci), 24(2), 246-255. https://doi.org/10.15218/zjms.2020.029
Section
Original Articles